(Q28145486)

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Steroid receptor regulated transcription of specific genes and gene networks

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Molecular mechanisms of action of steroid/thyroid receptor superfamily members

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Physical association and functional antagonism between the p65 subunit of transcription factor NF-kappa B and the glucocorticoid receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Negative regulation by glucocorticoids through interference with a cAMP responsive enhancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Antitumor promotion and antiinflammation: down-modulation of AP-1 (Fos/Jun) activity by glucocorticoid hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Transcriptional interference between c-Jun and the glucocorticoid receptor: mutual inhibition of DNA binding due to direct protein-protein interaction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A conserved AU sequence from the 3' untranslated region of GM-CSF mRNA mediates selective mRNA degradation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Mechanisms of action of glucocorticoids in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

New immunosuppressive drugs: mechanistic insights and potential therapeutic advances

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Negative transcriptional regulation of human interleukin 2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Inducible nitric oxide synthase is increased in murine lung epithelial cells by cytokine stimulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Expression of inducible nitric oxide in human lung epithelial cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

cDNA cloning and functional activity of a glucocorticoid-regulated inflammatory cyclooxygenase

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Induction of cyclo-oxygenase-2 by cytokines in human pulmonary epithelial cells: regulation by dexamethasone

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Cytosolic phospholipase A2 is coupled to hormonally regulated release of arachidonic acid

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Increased expression of endothelin in bronchial epithelial cells of asthmatic patients and effect of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Beta-adrenergic receptors and their regulation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Interleukin-1 type II receptor: a decoy target for IL-1 that is regulated by IL-4

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

The type II "receptor" as a decoy target for interleukin 1 in polymorphonuclear leukocytes: characterization of induction by dexamethasone and ligand binding properties of the released decoy receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Glucocorticoid-mediated repression of intercellular adhesion molecule-1 expression in human monocytic and bronchial epithelial cell lines

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Differential in vitro regulation by glucocorticoids of monocyte-derived cytokine generation in glucocorticoid-resistant bronchial asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Effect of corticosteroid treatment on interleukin-1 and tumour necrosis factor secretion by monocytes from subjects with asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Tumour necrosis factor in the bronchoalveolar secretions of infants with the respiratory distress syndrome and the effect of dexamethasone treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Glucocorticoids selectively inhibit the transcription of the interleukin 1 beta gene and decrease the stability of interleukin 1 beta mRNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Vasocortin: a novel glucocorticoid-induced anti-inflammatory protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Corticosteroid inhibition of airway microvascular leakage.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pharmacologic control of plasma exudation into tracheobronchial airways

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Heart rate depression during sleep apnea depends on hypoxic chemosensitivity. A study at high altitude.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Glucocorticoids and immune function: unknown dimensions and new frontiers

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Methylprednisolone achieves greater concentrations in the lung than prednisolone. A pharmacokinetic analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Early methylprednisolone treatment for septic syndrome and the adult respiratory distress syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Fibroproliferative phase of ARDS. Clinical findings and effects of corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Corticosteroid rescue treatment of progressive fibroproliferation in late ARDS. Patterns of response and predictors of outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

The role of the host defence response in the progression and outcome of ARDS: pathophysiological correlations and response to glucocorticoid treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Inflammatory cytokines in the BAL of patients with ARDS. Persistent elevation over time predicts poor outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Plasma and BAL cytokine response to corticosteroid rescue treatment in late ARDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A controlled study of the effects of single doses of hydrocortisone on the resolution of acute attacks of asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Controlled trial of intravenous corticosteroids in severe acute asthma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Glucocorticoid resistance in asthma

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Steroid resistance in asthma. Molecular mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Corticosteroids in acute severe asthma: effectiveness of low doses

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Steroids in COPD. The scripture according to Albert.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute effect of corticosteroids on respiratory mechanics in mechanically ventilated patients with chronic airflow obstruction and acute respiratory failure.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A randomized controlled trial of methylprednisolone in the emergency treatment of acute exacerbations of COPD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Outcome of intensive care in patients with HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary complications of the acquired immunodeficiency syndrome. Report of a National Heart, Lung, and Blood Institute workshop

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Corticosteroids prevent early deterioration in patients with moderately severe Pneumocystis carinii pneumonia and the acquired immunodeficiency syndrome (AIDS)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A controlled trial of early adjunctive treatment with corticosteroids for Pneumocystis carinii pneumonia in the acquired immunodeficiency syndrome. California Collaborative Treatment Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pneumocystis carinii pneumonia. Review of 53 cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pneumocystis carinii Pneumonia Among Patients Without AIDS at a Cancer Hospital

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Use of adjunctive corticosteroids in severe adult non-HIV Pneumocystis carinii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Complications of corticosteroid therapy in patients with the acquired immunodeficiency syndrome and Pneumocystis carinii pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

The effect of adjunctive corticosteroids for the treatment of Pneumocystis carinii pneumonia on mortality and subsequent complications

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Tuberculosis in patients with HIV infection who receive corticosteroids for presumed Pneumocystis carinii pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Consensus statement on the use of corticosteroids as adjunctive therapy for pneumocystis pneumonia in the acquired immunodeficiency syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute eosinophilic pneumonia as a reversible cause of noninfectious respiratory failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute eosinophilic pneumonia: a hypersensitivity phenomenon?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute eosinophilic pneumonia with respiratory failure: a new syndrome?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Transient wheeze. Eosinophilic bronchobronchiolitis in acute eosinophilic pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A clinical study of idiopathic eosinophilic pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute eosinophilic pneumonia. A summary of 15 cases and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute eosinophilic pneumonia: histopathologic findings in nine patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Fatal pulmonary aspergillosis presenting as acute eosinophilic pneumonia in a previously healthy child

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Hypersensitivity pneumonitis versus invasive pulmonary aspergillosis: two cases with unusual pathologic findings and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Diffuse alveolar hemorrhage and systemic lupus erythematosus. Clinical presentation, histology, survival, and outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary alveolar hemorrhage in systemic lupus erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Systemic lupus erythematosus: emerging concepts. Part 1: Renal, neuropsychiatric, cardiovascular, pulmonary, and hematologic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Wegener's Granulomatosis: Prospective Clinical and Therapeutic Experience With 85 Patients for 21 Years

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary capillaritis and alveolar hemorrhage. Update on diagnosis and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Wegener's granulomatosis presenting as diffuse pulmonary hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute fulminating intrapulmonary haemorrhage in Wegener's granulomatosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Wegener Granulomatosis: An Analysis of 158 Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Immune alveolar hemorrhage

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

21 January 2018

Small-vessel vasculitis

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

The pathologic spectrum of pulmonary lesions in patients with anti-neutrophil cytoplasmic autoantibodies specific for anti-proteinase 3 and anti-myeloperoxidase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Diffuse alveolar hemorrhage in autologous bone marrow transplant recipients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary complications in lymphoma patients treated with high-dose therapy autologous bone marrow transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Commentary and opinion: II. Statistical parametric mapping: ontology and current issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Open lung biopsy diagnosis of diffuse pulmonary infiltrates after marrow transplantation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute hypoxemic respiratory failure in children following bone marrow transplantation: an outcome and pathologic study

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Immunopathologic Studies of Pneumonitis in Systemic Lupus Erythematosus

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Bronchiolitis obliterans organising pneumonia: a clinical and radiological review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Bronchiolitis obliterans organizing pneumonia. Clinical features and differential diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Idiopathic bronchiolitis obliterans organizing pneumonia. Definition of characteristic clinical profiles in a series of 16 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Rapidly progressive bronchiolitis obliterans with organizing pneumonia

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Clinical spectrum of cryptogenic organising pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary radiation injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary Effects of Radiation Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Severe radiation injuries of the lung

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Modification of radiation injury to normal tissues by chemotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Radiation pneumonitis in mice. Some effects of corticosteroids on mortality and pulmonary physiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Severe tuberculosis in patients with human immunodeficiency virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Disseminated tuberculosis in the acquired immunodeficiency syndrome era.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A clinical review of bleomycin--a new antineoplastic agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Large-dose bleomycin therapy and pulmonary toxicity. A possible role of prior radiotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Fatal bleomycin toxicity from a low cumulative dose in a patient with renal insufficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Enhanced pulmonary toxicity with bleomycin and radiotherapy in oat cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Pulmonary complications after bleomycin, irradiation and surgery for esophageal cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Factors influencing postoperative morbidity and mortality in patients treated with bleomycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Bleomycin hypersensitivity pneumonitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Reversible Interstitial Pneumonitis Associated with Low Dose Bleomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Oxygen-Exacerbated Bleomycin Pulmonary Toxicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Interstitial pneumonia from mitomycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Carcinoma-associated hemolytic-uremic syndrome: a complication of mitomycin C chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

A syndrome of microangiopathic hemolytic anemia, renal impairment, and pulmonary edema in chemotherapy-treated patients with adenocarcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Mitomycin C-induced hemolytic uremic syndrome. Six case reports and review of the literature on renal, pulmonary and cardiac side effects of the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Mitomycin C and vindesine associated pulmonary toxicity with variable clinical expression

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Amiodarone pulmonary toxicity. Recognition and pathogenesis (Part I).

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Long-term efficacy and toxicity of high-dose amiodarone therapy for ventricular tachycardia or ventricular fibrillation

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Amiodarone-associated pulmonary toxicity. A clinical and pathologic study of eleven cases

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Crack lung: an acute pulmonary syndrome with a spectrum of clinical and histopathologic findings

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Crack lung: pulmonary disease caused by cocaine abuse

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Cocaine induced eosinophilic lung disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Cocaine-induced Churg-Strauss vasculitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Free-base cocaine use associated with bronchiolitis obliterans organizing pneumonia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

The pulmonary complications of crack cocaine. A comprehensive review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute myopathy associated with combined use of corticosteroids and neuromuscular blocking agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute myopathy during treatment of status asthmaticus with corticosteroids and steroidal muscle relaxants

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Acute corticosteroid myopathy in intensive care patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Systemic allergic reactions to corticosteroids

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Anaphylaxis after intravenous corticosteroid administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Adverse effects of corticosteroid therapy for COPD. A critical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Management of complications of glucocorticoid therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075

Are Intravenous Corticosteroids Required in Status Asthmaticus?

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FAJRCCM.160.4.9901075